Liese Barbier (European Medicines Agency)
Liese Barbier holds a position as seconded national expert at the European Medicines Agency in Amsterdam. Liese is part of the Oncology, Haematology and Diagnostics office of the Human Medicines Evaluation Division and focusses as product lead on the evaluation of biosimilar candidates in oncology. Further, Liese supports biosimilar initiatives across the Agency and coordinates the Biosimilar Medicinal Products Working Party. Liese holds a PhD candidate position at the Unit of Clinical Pharmacology and Pharmacotherapy at KU Leuven (Leuven, Belgium) and is part of the MABEL Fund research group. The MABEL fund (Fund on Market Analysis of Biologics & Biosimilars following Loss of Exclusivity) explores the market environment of originator biologicals and biosimilars following loss of exclusivity. Liese’s research focusses on the regulatory and market access challenges for biosimilar medicines and her PhD aims to formulate policy recommendations to support a long-term sustainable biologicals market with competition from biosimilars.
Liese Barbier obtained her Pharmacy degree at KU Leuven in 2015. After gaining clinical experience as a pharmacist, she started her PhD at KU Leuven in 2016. She has been working at the European Medicines Agency as a seconded national expert since January 2019.
Professor Carin A. Uyl-de Groot
Carin A. Uyl-de Groot studied Health Care Policy and Management at the Erasmus University Rotterdam. From March 1990 onwards she has been working at the Institute for Medical Technology Assessment (ITMA)/Department of Health Care Policy and Management at the Erasmus Medical Centre Rotterdam. Since March 2000 she has been director of the Institute for Medical Technology Assessment and in November 2005 she was appointed professor of health technology assessment at the VU University Medical Center in Amsterdam.
Her research activities are mainly focused on cost-effectiveness analyses of cancer treatments. Quality of life studies are an integral part of these studies. From 1994 she has been program leader of cancer studies. Her main interest consists of diagnostics and therapeutic technologies, economic studies linked to clinical studies, modelling studies, cost studies, quality of life studies, methodological issues and implementation studies particularly in the cancer field. She was awarded her PhD in 1995.
Professor Barbara Pierscionek
Professor Pierscionek graduated from Melbourne University and started her research career in Australia as an NHMRC research fellow (MRC equivalent) embracing interdisciplinary research. Barbara moved the medical research council grant and fellowship to an Engineering department, where she helped to develop optical and biomedical engineering courses.
She then moved to Faculty of Medicine at Monash University before coming to UK. Professor Pierscionek led the Vision Research group in Biomedical Science at Ulster University and was then appointed as the Associate Dean (Research and Enterprise) in the Faculty of Science, Engineering and Computing in Kingston University. Barbara led, directed and managed research across 8 schools which included all STEM disciplines, co-ordinated all REF activities, project managed design and building of new laboratories and developed enterprise.
Professor Pierscionek has continued as an active researcher in the areas of optics, vision, ageing, biomedical engineering, nanotechnology and Big Data. Whilst at Kingston, Barbara brought in grants from EU, charities, Royal Society and industry as well as being awarded beam time for work in Japan at the world’s largest synchrotron.
In addition to qualifications in science, she has an MBA and legal degree. Barbara’s research interests are in ethico-legal aspects of Big Data and vulunerable populations. She has also worked in the criminal justice system and as a lay judge in employment tribunals.
Associate Professor Ken Redekop
Ken Redekop is an associate professor at the Erasmus School of Health Policy and Management at Erasmus University (Rotterdam, The Netherlands). Ken is also Editor-in-Chief of Health Policy and Technology, a journal that primarily focusses on the policy implications of new and existing health technologies. Ken has worked in health technology assessment, health services research, observational research and clinical trials for more than 25 years and has co-authored more than 200 peer-reviewed articles.
Many of his recent projects have involved the assessment of innovative medical devices and diagnostic tests in various stages of development, using data from randomised controlled trials, observational studies and computer modelling. Current examples include four EU-funded Horizon 2020 projects that aim to translate new ideas about prognostic and predictive biomarkers, big data analytics and drug delivery into viable products and services that can improve health as well as healthcare efficiency.
Professor Donald Singer
Donald Singer is President of the Fellowship of Postgraduate Medicine, which publishes the Postgraduate Medical Journal (founded 1925) and Health Policy and Technology (founded 2012). The FPM celebrated its centenary at a conference in London in December 2018.
He is a Clinical Pharmacologist interested in new approaches to personalising medicine and in public understanding of health and drugs. He is a member of the panel of experts of the European Medicines Agency.
A member since 2013 of the Healthcare Professionals’ Working Party of the European Medicines Agency, he is involved in current EMA projects on minimizing risk from medicines. International consultancy includes advice on clinical pharmacology and safety systems for medicines as a Yale School of Medicine Faculty member within the 7 year Human Resources for Health US-AID and CDC supported programme in Rwanda.
He is a member Executive Committee of the European Association of Clinical Pharmacology and Therapeutics which supports scientific and educational exchange for over 4000 clinical pharmacologists from 34 countries. He was previously a member of the Council of the British Pharmacological Society and Panel Member of the NIHR Health Technology Assessment Programme.
Professor Ron F.J. de Winter PhD
Ron de Winter received his BSc Biochemistry in Feb. 1982 from the Univ. of Leiden and his PhD in Molecular Biology/Surrogate Genetics in Jan. 1987 from the Free University of Amsterdam and Portsmouth University, UK. This work resulted in a Cell publication in 1986.
He held positions as a Post-Doc with Ciba Geigy AG, Switzerland cloning and expressing mouse-human chimeric antibodies, and as industrial R&D Manager with Unilever UK, humanizing anti-cancer mouse monoclonal antibodies.
Further experience includes 15 years in Food R&D and Quality Assurance management and 10 years of clinical study management a.o. as Project Director of the vaccination study CAPiTA with Julius Clinical BV, a study where 85.000 healthy senior citizens were recruited and followed up for pneumonia.
Since May 2012 he is with University Medical Center Utrecht (UMCU) as Programme Manager for European projects, currently for 5 IMI public-privately funded projects on multinational clinical trials with new agents against multi-resistant bacteria, both gram-positive and gram-negative, and 3 European publicly funded projects.